Таргетная терапия системной красной волчанки: настоящее и будущее

DOI: https://doi.org/10.29296/25877305-2021-11-03
Скачать статью в PDF
Номер журнала: 
11
Год издания: 
2021

Н.А. Куницкая, доктор медицинских наук Северо-Западный государственный медицинский университет
им. И.И. Мечникова Минздрава России, Санкт-Петербург E-mail: scvssd@yandex.ru

Системная красная волчанка (СКВ) – аутоиммунное системное заболевание, патогенез которого основан на дефектах иммунорегуляции, приводящих к неконтролируемой гиперпродукции аутоантител к компонентам собственных тканей и развитию хронического воспаления, поражающего многие органы и системы. Пристальный интерес к СКВ в последние десятилетия позволил усовершенствовать методы ее диагностики, однако ведение пациентов по-прежнему остается сложной задачей. Разработке методов лечения препятствуют неизвестная этиология заболевания, большая вариабельность клинических проявлений, возможность как длительных спонтанных ремиссий, так и злокачественного, быстро прогрессирующего, иногда молниеносного течения. Для терапии СКВ в настоящее время используется практически весь арсенал противовоспалительных и цитотоксических препаратов, существующих в медицине, применение которых значительно улучшает прогноз жизни пациентов. Современные методы лечения направлены на подавление аутоиммунного воспаления, предотвращение рецидивов и уменьшение клинических симптомов и необратимого повреждения органов. В обзоре освещаются иммунные механизмы, преобладающие в новых целевых методах лечения СКВ.
Ключевые слова: 
терапия
системная красная волчанка
клинические исследования
моноклональные антитела
экулизумаб
ритуксимаб
белимумаб
обинтузумаб
табалумаб
атаксицепт
бортезомиб
анифролумаб
сифалимумаб
ронтализумаб
Для цитирования
Н.А. Куницкая Таргетная терапия системной красной волчанки: настоящее и будущее . Врач, 2021; (11): 18-23 https://doi.org/10.29296/25877305-2021-11-03

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Козлов В.А., Савченко А.А., Кудрявцев И.В. и др. Клиническая иммунология. Красноярск: Поликор, 2020; 386 с. [Kozlov V.A., Savchenko A.A., Kudryavtsev I.V. et al. Klinicheskaya immunologiya. Krasnoyarsk: Polikor, 2020; 386 s. (in Russ.)]. DOI: 10.17513/np.438
  2. Alexander T., Cheng Q., Klotsche J. et al. Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur J Immunol. 2018; 48: 1573–9. DOI: 10.1002/eji.201847492
  3. Alshaiki F., Obaid E., Almuallim A. et al. Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol. 2018; 5: 118–26. DOI: 10.5152/eurjrheum.2018.17096
  4. Aranow C., Dall’Era M., Byron M. et al. FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis. Ann Rheum Dis. 2018; 77: 690.
  5. Banchereau R., Hong S., Cantarel B. et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell. 2016; 165 (3): 551–65. DOI: 10.1016/j.cell.2016.03.008
  6. Buyon J.P., Cohen P., Merrill J.T. et al. A highlight from the LUPUS 2014 meeting: eight great ideas. Lupus Sci Med. 2015; 2 (1): e000087. DOI: 10.1136/lupus-2015-000087
  7. Collins C.E., Dall’Era M., Kan H. et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016; 3 (1): e000118. DOI: 10.1136/lupus-2015-000118
  8. Clowse M.E., Wallace D.J., Furie R.A. et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 2017; 69: 362–75. DOI: 10.1002/art.39856
  9. D’Cruz D., Maksimowicz-McKinnon K., Oates J. et al. Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the EMBRACE study. Lupus Sci Med. 2019; 6: A149–A150. DOI: 10.1136/lupus-2019-lsm.200
  10. Doria A., Stohl W., Schwarting A. et al. Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, cypocomplementemic patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018; 70 (8): 1256–64. DOI: 10.1002/art.40511
  11. Dorner T., Shock A., Goldenberg D.M. et al. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmun Rev. 2015; 14: 1079–86. DOI: 10.1016/j.autrev.2015.07.013
  12. Ehrenstein M.R., Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016; 12 (6): 367–72. DOI: 10.1038/nrrheum.2016.18
  13. Everly M.J., Everly J.J., Susskind B. et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008; 86 (12): 1754–61. DOI: 10.1097/TP.0b013e318190af83
  14. Fanouriakis A., Kostopoulou M., Alunno A. et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019; 78 (6): 736–45. DOI: 10.1136/annrheumdis-2019-215089
  15. Fanouriakis A., Kostopoulou M., Cheema K. et al. 2019 Update of the joint European league against rheumatism and european renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020; 79 (6): 713–23. DOI: 10.1136/annrheumdis-2020-216924
  16. Furie R., Aroca G., Alvarez A. et al. A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis. Arthritis Rheumatol. 2019; 71 (10): 9–39.
  17. Furie R.A., Leon G., Thomas M. et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015; 74 (9): 1667–75. DOI: 10.1136/annrheumdis-2013-205144
  18. Furie R., Merrill J., Werth V. et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus. Arthritis Rheumatol. 2015; 67: 3223. DOI: 10.1002/art.39962
  19. Furie R.A., Morand E.F., Bruce I.N. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019; 208–19. DOI: 10.1016/S2665-9913(19)30076-1
  20. GlaxoSmithKline. GSK Announces Positive Headline Results in Phase 3 Study of Benlysta in Patients with Lupus Nephritis, 2019. Available online at: https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-in-phase-3-study-of-benlysta-in-patients-with-lupus-nephritis
  21. Gomez Mendez L.M., Cascino M.D., Garg J. et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018; 13 (10): 1502–9. DOI: 10.2215/CJN.01070118
  22. Greenbaum L.A., Fila M., Ardissino G. et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016; 89 (3): 701–11. DOI: 10.1016/j.kint.2015.11.026
  23. Hennessey A., Lukawska J., Cambridge G. et al. Advers infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis. BMC Rheumatol. 2019; 3: 32. DOI: 10.1186/s41927-019-0082-7
  24. Houssiau F.A., Doria A. Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty? Ann Rheum Dis. 2016; 75 (2): 321–2. DOI: 10.1136/annrheumdis-2015-208312
  25. Iaccarino L., Bettio S., Reggia R. et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. 2017; 69 (1): 115–23. DOI: 10.1002/acr.22971
  26. Isenberg D.A., Petri M., Kalunian K. et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75 (2): 323–31. DOI: 10.1136/annrheumdis-2015-207653
  27. Ishii T., Tanaka Y., Kawakami A. et al. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol. 2018; 28 (6): 986–92. DOI: 10.1080/14397595.2018.1432331
  28. Jones A., Muller P., Dore C.J. et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019; 9 (12): e032569. DOI: 10.1136/bmjopen-2019-032569
  29. Kalunian K.C., Merrill J.T., Maciuca R. et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016; 75 (1): 196–202. DOI: 10.1136/annrheumdis-2014-206090
  30. Kalunian K.C., Merrill J.T., Maciuca R. et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016; 75 (1): 196–202. DOI: 10.1136/annrheumdis-2014-206090
  31. Kansal R., Richardson N., Neeli I. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019; 11 (482): eaav1648. DOI: 10.1126/scitranslmed.aav1648
  32. Khamashta M., Merrill J.T., Werth V.P. et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75 (11): 1909–16. DOI: 10.1136/annrheumdis-2015-208562
  33. Kraaij T., Kamerling S.W.A., de Rooij E.N.M. et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018; 91: 45–54. DOI: 10.1016/j.jaut.2018.03.003
  34. Kavanagh D., Smith-Jackson K. Eculizumab in children with hemolytic uremic syndrome. Kidney Int. 2016; 89 (3): 537–8. DOI: 10.1016/j.kint.2015.12.039
  35. Licht C., Greenbaum L.A., Muus P. et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015; 87 (5): 1061–73. DOI: 10.1038/ki.2014.423
  36. Masoud S., McAdoo S.P., Bedi R. et al. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology. 2018; 57 (7): 1156–61. DOI: 10.1093/rheumatology/key042
  37. Merrill J.T., Shanahan W.R., Scheinberg M. et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018; 77 (6): 883–9. DOI: 10.1136/annrheumdis-2018-213032
  38. Merrill J.T., van Vollenhoven R.F., Buyon J.P. et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75 (2): 332–40. DOI: 10.1136/annrheumdis-2015-207654
  39. Morand E.F., Furie R., Tanaka Y. et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020; 382 (3): 211–21. DOI: 10.1056/NEJMoa1912196
  40. Murphy G., Isenberg D.A. New therapies for systemic lupus erythematosus – past imperfect, future tense. Nat Rev Rheumatol. 2019; 15 (7): 403–12. DOI: 10.1038/s41584-019-0235-5
  41. Parodis I., Soder F., Faustini F. et al. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL. Lupus. 2018; 27 (9): 1470–8. DOI: 10.1177/0961203318777116
  42. Parodis I., Sjowall C., Jonsen A. et al. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev. 2017; 16 (4): 343–51. DOI: 10.1016/j.autrev.2017.02.005
  43. Parodis I., Gomez A., Frodlund M. et al. Smoking reduces the efficacy of belimumab in mucocutaneous lupus. Expert Opin Biol Ther. 2018; 18 (8): 911–20. DOI: 10.1080/14712598.2018.1494719
  44. Parodis I., Johansson P., Gomez A. et al. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Rheumatology. 2019; 58 (12): 2170–76. DOI: 10.1093/rheumatology/kez191
  45. Parodis I., Gomez A., Emamikia S. et al. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. Ann Rheum Dis. 2019; 78 (7): 1006–7. DOI: 10.1136/annrheumdis-2018-214880
  46. Parodis I., Åkerström E., Sjöwall C. et al. Autoantibody and cytokine profiles during treatment with belimumab in patients with systemic lupus erythematosus. Int J Mol Sci. 2020; 21 (10): 3463. DOI: 10.3390/ijms21103463
  47. Ramskold D., Parodis .I, Lakshmikanth T. et al. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine. 2019; 40: 517–27. DOI: 10.1016/j.ebiom.2018.12.035
  48. Reddy V., Dahal L.N., Cragg M.S. et al. Optimising Bcell depletion in autoimmune disease: is obinutuzumab the answer? Drug Discov Today. 2016; 21 (8): 1330–8. DOI: 10.1016/j.drudis.2016.06.009
  49. Scheinberg M.A., Hislop C.M., Martin R.S. Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser. Expert Opin Biol Ther. 2016; 16 (5): 723–33. DOI: 10.1517/14712598.2016.1169270
  50. Schweighoffer E., Tybulewicz V.L. Signalling for B cell survival. Curr Opin Cell Biol. 2018; 51: 8–14. DOI: 10.1016/j.ceb.2017.10.002
  51. Stohl W., Schwarting A., Okada M. et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017; 69 (5): 1016–27. DOI: 10.1002/art.40049
  52. Sohrabian A., Parodis I., Carlstromer-Berthen N. et al. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Res Ther. 2019; 21 (1): 259. DOI: 10.1186/s13075-019-2056-y
  53. Teng Y.K.O., Bruce I.N., Diamond B. et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019; 9 (3): e025687. DOI: 10.1136/bmjopen-2018-025687
  54. Touma Z., Sayani A., Pineau C.A. et al. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada study. Rheumatol Int. 2017; 37 (6): 865–73. DOI: 10.1007/s00296-017-3682-9
  55. von Kempis J., Duetsch S., Reuschling N. et al. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland. Swiss Med Wkly. 2019; 149: w20022. DOI: 10.4414/smw.2019.20022